This study investigated the regulatory role of the LOXL2 subfactors in maintaining drug resistance in gemcitabine-resistant pancreatic cancer and aimed to elucidate the induction mechanism leading to LOXL2 overexpression. Here, LOXL2 is linked to familial pancreatic carcinoma.